Home › All Companies › CNTX › Annual Report

Context Therapeutics Inc. (CNTX) — Annual Report

AI-Powered SEC Filing Analysis

← All CNTX filings
Latest Annual Report Filed: 2026-03-23

Key Insights

  • Context Therapeutics is developing a pipeline of antibody-based therapies, including CTIM76, CT95, and CT202, with potential to address various oncology indications.
  • The company has secured financing through private placements and at-the-market offerings, providing capital to fund its research and development activities.
  • Context Therapeutics has entered into collaborative agreements with Integral Molecular Inc. and BioAtla Inc. to advance its pipeline, potentially unlocking additional value for shareholders.
Sentiment: Positive Significance: 7/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-03-23. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Context Therapeutics Inc.

Quarterly Report Current Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.